Mydecine Innovations Group Stock Shares Outstanding
| MYCOF Stock | USD 0.01 0 25.00% |
Mydecine Innovations Group fundamentals help investors to digest information that contributes to Mydecine Innovations' financial success or failures. It also enables traders to predict the movement of Mydecine Pink Sheet. The fundamental analysis module provides a way to measure Mydecine Innovations' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mydecine Innovations pink sheet.
Mydecine |
Mydecine Innovations Group Company Shares Outstanding Analysis
Mydecine Innovations' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Mydecine Innovations Shares Outstanding | 13.01 M |
Most of Mydecine Innovations' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mydecine Innovations Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Mydecine Innovations Group has 13.01 M of shares currently outstending. This is 92.8% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 97.73% higher than that of the company.
Mydecine Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mydecine Innovations' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mydecine Innovations could also be used in its relative valuation, which is a method of valuing Mydecine Innovations by comparing valuation metrics of similar companies.Mydecine Innovations is currently under evaluation in shares outstanding category among its peers.
Mydecine Fundamentals
| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 | |||
| Current Valuation | 8.64 M | |||
| Shares Outstanding | 13.01 M | |||
| Shares Owned By Insiders | 8.71 % | |||
| Price To Book | 23.41 X | |||
| Price To Sales | 677.59 X | |||
| Revenue | 7.49 K | |||
| Gross Profit | 7.49 K | |||
| EBITDA | (23.14 M) | |||
| Net Income | (28.9 M) | |||
| Cash And Equivalents | 324.15 K | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 1.26 X | |||
| Book Value Per Share | (0.36) X | |||
| Cash Flow From Operations | (24.05 M) | |||
| Earnings Per Share | (4.68) X | |||
| Target Price | 140.0 | |||
| Number Of Employees | 11 | |||
| Beta | 3.42 | |||
| Market Capitalization | 5.94 M | |||
| Total Asset | 7.58 M | |||
| Z Score | -9.3 | |||
| Net Asset | 7.58 M |
About Mydecine Innovations Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mydecine Innovations Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mydecine Innovations using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mydecine Innovations Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.